FDA approves Pepaxto for patients with relapsed or refractory multiple myeloma – Oncopeptides AB
Oncopeptides AB (publ) – announced that the FDA, has approved Pepaxto (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with… read more.
